Group 1: R&D and Product Development - The company has made significant breakthroughs in R&D in 2024, focusing on optimizing product pipelines and advancing innovative drug projects, including multiple biopharmaceutical research systems in ophthalmology, pediatrics, and neurology [2][3] - A novel ophthalmic biopharmaceutical is preparing for Phase III clinical trials [2] Group 2: Impact of Production Suspension - The suspension of production and sales at Tianjin Weiming will adversely affect sales and cash flow, pending completion of rectification and inspection by regulatory authorities [3] - If production does not resume within three months, the company may trigger risk warnings under the Shenzhen Stock Exchange rules [3] Group 3: Financial Performance - In 2024, the company reported a net loss of CNY 137 million, primarily due to asset impairment losses of CNY 105 million [4] - Cash reserves increased significantly due to dividend receipts, despite the negative net profit [4] Group 4: Legal and Compliance Issues - The company has fully provisioned for liabilities related to a recent lawsuit, ensuring no negative impact on 2025 profits [4] - The company is actively pursuing legal measures to mitigate the impact of the lawsuit and protect shareholder interests [4] Group 5: Corporate Governance and Shareholder Rights - The company has opted not to distribute profits for 2024 due to negative net profit, focusing on sustainable development and shareholder interests [5] - The recent amendments to Beijing Kexing's articles of association are aimed at enhancing operational standards and do not adversely affect shareholder interests [4][5] Group 6: Stock and Investment Matters - The company is addressing the issue of non-standard financial reporting and clarifying that Beijing Kexing is an associate, not a subsidiary, hence not consolidated in financial statements [6] - The company is progressing on stock lock-up release matters in accordance with legal regulations [6]

证券代码：002581 证券简称：未名医药 公告编号：2025-031 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，山东未名生物医药股份有限公司（以下 简称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现将 相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP,参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。 届时公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、 融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交 流，欢迎广大投资者踊跃参与！ 山东未名生物医药股份有限公司 关于参加 2025 年山东辖区上市公司投资者 网上集体接待日活动的公告 特此公告！ 山东未名生物医药股份有限公司 董事会 2025 年 5 月 ...

Market Performance - The Shanghai Composite Index and Shenzhen Component Index experienced declines of 0.30% and 0.69% respectively on May 5, 2025, while the ChiNext Index and STAR Market 50 fell by 0.87% and 1.96% respectively [1] - Among 33 A-share companies in Zibo, 30 saw an increase, 1 remained flat, and 2 declined during the same period [1] Notable Stock Movements - Weiming Pharmaceutical (002581) achieved a remarkable 23.29% increase over five days, leading the gains [1] - Yahua Electronics (301337) and Jincheng Pharmaceutical (300233) also saw significant increases of 17.30% and 11.31% respectively [1] - On May 7, PEEK material concept stocks surged, with Zhongxin Fluorine Materials (002915) hitting the daily limit for the sixth time in nine days, and Kaisheng New Materials (301069) rising by 2.29% with a trading volume of 4.02 billion yuan [1] Company Announcements - Kehui Co., Ltd. announced a share repurchase plan with a budget between 9 million and 16 million yuan, with a maximum repurchase price of 17 yuan per share, aimed at employee stock ownership plans [1] Financial Results - Furuida (600223) reported a revenue of 526 million yuan in its cosmetics segment for Q1 2025, with a gross margin of 61.06% [3] - Qichang Tenda (002408) achieved total revenue of 5.618 billion yuan in Q1 2025, a year-on-year increase of 2.53%, but saw a significant drop in net profit by 83.18% to 5.4007 million yuan [3] - Xinhua Medical (600587) reported a total revenue of 2.308 billion yuan, down 8.74% year-on-year, with a net profit decline of 23.97% to 160 million yuan [3] - Bohui Paper (600966) reported a total revenue of 4.564 billion yuan, a 3.77% increase year-on-year, but a net profit decline of 46.91% to 53.3737 million yuan [3] Market Capitalization - In terms of market capitalization, Yingke Medical (300677) led with 14.708 billion yuan, followed closely by Shandong Pharmaceutical Glass (600529) at 14.626 billion yuan, and Qichang Tenda (002408) at 12.963 billion yuan [4]

证券代码：002581 证券简称：未名医药 公告编号：2025-030 一、本次诉讼的基本情况 2024 年 2 月，自然人沈祥鑫与山东未名生物医药股份有限公司（以下简称 "公司"）因缔约过失发生纠纷，对公司提起诉讼。2024 年 9 月 29 日，公司收 到浙江省杭州市上城区人民法院《民事判决书》（2024）浙 0102 民初 2640 号， 判决驳回沈祥鑫全部诉讼请求。应收案件受理费 224,703 元，由原告沈祥鑫负担。 原告不服民事判决，向中级人民法院提起上诉。 山东未名生物医药股份有限公司 关于涉及诉讼事项的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、案件所处的诉讼阶段：再审已受理 2、公司所处的当事人地位：再审申请人 3、涉及的金额：3,048.02 万元 4、对上市公司损益产生的影响：公司已根据本次诉讼事项二审判决全额计 提预计负债和损失，不会对公司本期利润及期后利润产生负面影响。 近期，公司收到浙江省杭州市中级人民法院《民事判决书》（2024）浙 01 民 终 11002 号，判决如下：一、撤销浙江省杭州市上城区 ...

证券代码：002581 证券简称：未名医药 公告编号：2025-029 山东未名生物医药股份有限公司 关于股价异动及风险提示的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 公司控股子公司天津未名出现被暂停生产、销售与产品被取消集采中选资格 事项，根据《深圳证券交易所股票上市规则》（2024 年修订）9.8.1 条第（五） 项规定：公司生产经营活动受到严重影响且预计在三个月内不能恢复正常，公司 股票将被实施其他风险警示。公司因天津未名停产导致主营业务受到严重影响。 截止本公告披露之日，公司仍具有生产经营的能力，且天津未名预计停产时间不 超过三个月。如天津未名三个月内无法恢复生产，则公司可能触发其他风险警示 的情形。 一、股票交易异常波动的情况 山东未名生物医药股份有限公司（以下简称"公司"）股票交易价格于 2025 年 4 月 25 日、2025 年 4 月 28 日、2025 年 4 月 29 日连续三个交易日收盘价格涨 跌幅偏离值累计超过 20%，根据深圳证券交易所的有关规定，属于股票交易异常 波动的情况。 二、公司关注并核实相关情 ...

Core Viewpoint - The recent announcement by Weiming Pharmaceutical reveals that its core subsidiary, Tianjin Weiming, has been ordered to cease production and sales due to quality defects, highlighting the shift in the pharmaceutical industry towards prioritizing quality over price in drug procurement [1][4]. Group 1: Company Impact - Tianjin Weiming, as a core asset of Weiming Pharmaceutical, faced significant operational challenges after its interferon α2b spray, which was expected to generate substantial revenue, was halted due to quality issues [2][5]. - The interferon product was projected to contribute 229 million yuan in revenue for 2024, accounting for 64.27% of the company's total revenue, but the recall has already reduced current income by 23.16 million yuan [2][5]. - The company has reported continuous losses for three years, with a net loss of 155 million yuan in 2024, and risks being classified as ST if production halts exceed three months, which would freeze its financing channels [3][5]. Group 2: Industry Context - The incident coincides with a critical transition in national drug procurement policies, emphasizing quality over low pricing, as indicated by the new guidelines released on March 27 [4]. - The case of Weiming Pharmaceutical serves as a cautionary tale for the industry, illustrating the inherent conflict between low-price bidding and quality assurance, especially as the procurement landscape shifts towards a "quality-first" approach [4][5]. - The company's failure to address the quality issues publicly has raised investor concerns and skepticism regarding its financial integrity, further complicating its position in a changing regulatory environment [5].

Core Viewpoint - Shandong Weiming Pharmaceutical Co., Ltd. is facing significant operational challenges due to regulatory actions against its subsidiary Tianjin Weiming, which has been suspended from production and sales, impacting the company's revenue heavily [1][3][5]. Group 1: Regulatory Actions - Tianjin Weiming was subjected to production and sales suspension by the Tianjin Drug Administration due to non-compliance with Good Manufacturing Practice (GMP) standards [3]. - The core product, human interferon α2b spray, has faced procurement suspensions from Inner Mongolia and Tibet due to unsatisfactory inspection results [2][3]. - The company has previously experienced similar issues, with the Jiangxi Provincial Procurement Office announcing that the interferon α2b spray did not meet biological activity standards [4][8]. Group 2: Financial Impact - In 2024, Tianjin Weiming is projected to generate revenue of 217 million yuan, accounting for 60.09% of Weiming Pharmaceutical's total revenue [3][6]. - The recall of the interferon α2b spray has already reduced the company's revenue by 23.17 million yuan in 2024, with further implications for 2025 sales [5]. - Weiming Pharmaceutical has reported continuous losses for three consecutive years, with a record loss of 332 million yuan in 2023 [6][8]. Group 3: Product and Market Dynamics - The interferon product line is crucial for Weiming Pharmaceutical, contributing significantly to its revenue, with a gross margin of 79.92% in 2024 [7]. - The company has been involved in a competitive procurement process for interferon products, with the interferon α2b spray being the only product to win a bid at a price of 33.58 yuan for a specific volume [8]. - The procurement process, known as "small country procurement," has introduced uncertainties regarding the future of the company's core products due to the recent regulatory issues [8][9]. Group 4: Stock Market Reaction - Following the announcement of the production suspension, Weiming Pharmaceutical's stock fell to a limit down, closing at 6.68 yuan per share, with a total market capitalization of 4.407 billion yuan [10].

证券代码：002581 证券简称：未名医药 公告编号：2025-025 山东未名生物医药股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2024年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：公司2024年度股东大会会议的召集、召开符 合《公司法》等法律、法规、规范性文件和《公司章程》的有关规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025年5月19日下午2:30 （2）网络投票时间： ①通过深圳证券交易所交易系统进行投票的时间：2025年5月19日上午 9:15-9:25，9:30-11:30，下午1:00-3:00； ②通过互联网投票系统进行网络投票的时间：2025年5月19日9:15-15:00。 5、会议的召开方式：本次股东大会采用现场表决与网络投票相结合的方式 召开。 6、会议的股权登记日：2025年5月14日 7、出席对象： | 提案编码 | 提案名称 | 备注 | | --- | --- | --- | ...

证券代码：002581 证券简称：未名医药 公告编号：2025-027 山东未名生物医药股份有限公司(以下简称"公司")第五届监事会第二十三 次会议于 2025 年 4 月 28 日上午 11 时以通讯方式召开。应参加表决监事 3 名， 实际参加表决监事 3 人，分别为：柯莹、闫雪明、彭龙。监事会会议通知已于 2025 年 4 月 25 日以通讯方式发出，会议由公司监事主席柯莹女士主持。本次监事会 的召集和召开符合国家有关法律、法规、《监事会议事规则》及《公司章程》的 规定。本次会议逐项审议了如下议案： 二、监事会会议审议情况 山东未名生物医药股份有限公司 第五届监事会第二十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 （一）审议通过了《2025 年第一季度报告》 本次注销事项在公司 2023 年第一次临时股东大会决议对董事会的授权范围 内，已经公司第五届董事会薪酬与考核委员会第九次会议审议通过，无需提交股 东大会审议。具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）上披露的 《关于 2023 年 ...

证券代码：002581 证券简称：未名医药 公告编号：2025-026 山东未名生物医药股份有限公司 第五届董事会第三十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东未名生物医药股份有限公司(以下简称"公司")第五届董事会第三十六 次会议于 2025 年 4 月 28 日上午 10 时以通讯方式召开。应参加表决董事 11 名， 实际参加表决董事 11 人，分别为：岳家霖、刘文俊、黄桂源、岳莹、于秀媛、 于文杰、蔡艳红、张荣富、刘洋、夏阳、赵辉。董事会会议通知已于 2025 年 4 月 25 日以通讯方式发出，会议由公司董事长岳家霖先生主持。本次董事会的召集 和召开符合国家有关法律、法规、《董事会议事规则》及《公司章程》的规定。 本次会议逐项审议了如下议案： 二、董事会会议审议情况 （一）审议通过了《2025 年第一季度报告》 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）上披露的《2025 年第 一季度报告》。 表决情况：同意 11 票,反对 0 票,弃权 0 票。 表决结果：通过。 （二） ...